|
gptkbp:instanceOf
|
gptkb:drug
benzodiazepine
|
|
gptkbp:activeIngredient
|
gptkb:flurazepam
|
|
gptkbp:approvedBy
|
1970 (US)
|
|
gptkbp:ATCCode
|
gptkb:N05CD01
|
|
gptkbp:brand
|
gptkb:Dalmane
|
|
gptkbp:CASNumber
|
gptkb:17617-23-1
|
|
gptkbp:contraindication
|
gptkb:myasthenia_gravis
pregnancy
severe hepatic impairment
severe respiratory insufficiency
sleep apnea syndrome
|
|
gptkbp:controlledSubstanceSchedule
|
Schedule IV (US)
|
|
gptkbp:eliminationHalfLife
|
40-250 hours (active metabolite)
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:hasMolecularFormula
|
C21H23ClFN3O.HCl
|
|
gptkbp:hasSaltForm
|
hydrochloride
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
flurazepam hydrochloride
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
GABA-A receptor positive allosteric modulator
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
3386
DB00690
|
|
gptkbp:riskFactor
|
dependence
withdrawal symptoms
next-day impairment
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
dizziness
fatigue
headache
drowsiness
|
|
gptkbp:UNII
|
U7QF7M82PW
|
|
gptkbp:usedFor
|
insomnia
|
|
gptkbp:bfsParent
|
gptkb:flurazepam
|
|
gptkbp:bfsLayer
|
7
|